User profiles for Danniel Zamora
 | Danniel zamoraAssociate, Fred Hutch Cancer Center Verified email at fredhutch.org Cited by 335 |
[HTML][HTML] Clinical, laboratory, and temporal predictors of neutralizing antibodies against SARS-CoV-2 among COVID-19 convalescent plasma donor candidates
…, C Morishima, S Selke, D Zamora… - The Journal of …, 2021 - Am Soc Clin Investig
BACKGROUND SARS-CoV-2–specific antibodies may protect from reinfection and disease,
providing rationale for administration of plasma containing SARS-CoV-2–neutralizing …
providing rationale for administration of plasma containing SARS-CoV-2–neutralizing …
Cytomegalovirus-specific T-cell reconstitution following letermovir prophylaxis after hematopoietic cell transplantation
D Zamora, ER Duke, H Xie, BC Edmison… - Blood, The Journal …, 2021 - ashpublications.org
Decreased cytomegalovirus (CMV)-specific immunity after hematopoietic cell transplantation
(HCT) is associated with late CMV reactivation and increased mortality. Whether letermovir …
(HCT) is associated with late CMV reactivation and increased mortality. Whether letermovir …
Depletion of exhausted alloreactive T cells enables targeting of stem-like memory T cells to generate tumor-specific immunity
Some hematological malignancies such as multiple myeloma are inherently resistant to
immune-mediated antitumor responses, the cause of which remains unknown. Allogeneic bone …
immune-mediated antitumor responses, the cause of which remains unknown. Allogeneic bone …
Delayed-onset cytomegalovirus infection is frequent after discontinuing letermovir in cord blood transplant recipients
Cytomegalovirus (CMV)-seropositive umbilical cord blood transplantation (CBT) recipients
have a high incidence of CMV-associated complications. There are limited data regarding the …
have a high incidence of CMV-associated complications. There are limited data regarding the …
Inhibition of Pseudomonas aeruginosa by peptide-conjugated phosphorodiamidate morpholino oligomers
…, KR Marshall-Batty, CF Felder, D Zamora… - Antimicrobial agents …, 2017 - Am Soc Microbiol
Pseudomonas aeruginosa is a highly virulent, multidrug-resistant pathogen that causes
significant morbidity and mortality in hospitalized patients and is particularly devastating in …
significant morbidity and mortality in hospitalized patients and is particularly devastating in …
Cytomegalovirus breakthrough and resistance during letermovir prophylaxis
Letermovir is a relatively new antiviral for prophylaxis against cytomegalovirus (CMV) after
allogeneic hematopoietic cell transplantation (HCT). CMV-seropositive HCT recipients who …
allogeneic hematopoietic cell transplantation (HCT). CMV-seropositive HCT recipients who …
Peptide-Conjugated Phosphorodiamidate Morpholino Oligomers Retain Activity against Multidrug-Resistant Pseudomonas aeruginosa In Vitro and In Vivo
Most antimicrobials currently in the clinical pipeline are modifications of existing classes of
antibiotics and are considered short-term solutions due to the emergence of resistance. …
antibiotics and are considered short-term solutions due to the emergence of resistance. …
Impact of GVHD prophylaxis on CMV reactivation and disease after HLA-matched peripheral blood stem cell transplantation
M Ueda Oshima, H Xie, D Zamora, ME Flowers… - Blood …, 2023 - ashpublications.org
The kinetics of early and late cytomegalovirus (CMV) reactivation after hematopoietic cell
transplantation using various methods of graft-versus-host-disease (GVHD) prophylaxis are …
transplantation using various methods of graft-versus-host-disease (GVHD) prophylaxis are …
Human herpesvirus-6 reactivation and disease after allogeneic haematopoietic cell transplantation in the era of letermovir for cytomegalovirus prophylaxis
Objectives Letermovir for cytomegalovirus (CMV) prophylaxis in allogeneic haematopoietic
cell transplant (HCT) recipients has decreased anti-CMV therapy use. Contrary to letermovir, …
cell transplant (HCT) recipients has decreased anti-CMV therapy use. Contrary to letermovir, …
Late Cytomegalovirus Disease after Hematopoietic Cell Transplantation: Significance of Novel Transplantation Techniques
…, S Özkök, H Xie, WM Leisenring, D Zamora… - Blood …, 2024 - ashpublications.org
Pre-emptive therapy (PET) and letermovir prophylaxis are effective in preventing CMV disease
within the first 100 days after allogeneic hematopoietic cell transplantation (HCT) but are …
within the first 100 days after allogeneic hematopoietic cell transplantation (HCT) but are …
